甲状腺疾患治療の世界市場：2024年～2031年

レポート概要

世界の甲状腺疾患治療の市場規模は、2023年に27億米ドルに達し、2031年には43億米ドルに達すると予測され、予測期間2024年～2031年のCAGRは6.3%で成長する見込みです。

甲状腺疾患治療には、甲状腺機能低下症、甲状腺機能亢進症、甲状腺結節、甲状腺がんなどの甲状腺機能異常を治療するための医学的介入が含まれます。治療には、ホルモン補充療法、抗甲状腺薬、放射性ヨード、手術療法などがあります。分子標的治療法の進歩により、治療の精度が向上し、患者に合った解決策が提供されるようになりました。これらの治療は、甲状腺ホルモン産生の障害によって引き起こされる代謝の不均衡に対処するものです。

市場力学：

促進要因と抑制要因

甲状腺疾患の有病率の上昇

世界の甲状腺疾患治療市場は、甲状腺機能低下症、甲状腺機能亢進症、甲状腺結節、甲状腺がんなどの甲状腺疾患の有病率の増加により成長を経験しています。人口の高齢化、遺伝的素因、橋本甲状腺炎やバセドウ病のような自己免疫疾患のような要因が、この増加に寄与しています。

例えば、米国甲状腺協会によると、米国人口の12％以上が甲状腺疾患を発症し、200億人の米国人が何らかの甲状腺疾患を持っています。甲状腺疾患のある人の60%までが、自分の症状に気づいていません。女性は男性の5～8倍甲状腺の病気にかかりやすいです。8人に1人の女性が甲状腺疾患を発症します。

ほとんどの甲状腺がんは治療に反応しますが、ごく一部は侵攻性があります。未診断の甲状腺疾患は、心血管疾患、骨粗鬆症、不妊症などの深刻な状態につながる可能性があります。甲状腺機能低下症と診断されていない、あるいは治療が不十分な妊婦は、流産や早産のリスクが高くなります。

薬剤に伴う合併症

甲状腺の病気は、治療法によってさまざまな副作用をもたらします。甲状腺機能低下症に使われるホルモン補充療法は、体重増加、脱毛、動悸、不安、不眠を引き起こすことがあります。メチマゾールやプロピルチオウラシルのような抗甲状腺薬は、肝臓毒性、皮膚の発疹、関節痛、白血球数の減少を引き起こし、感染症のリスクを高めます。放射性ヨード療法は長期的な甲状腺機能低下症につながる可能性があり、生涯にわたるホルモン補充を必要とし、口の渇き、唾液腺の炎症、味覚の変化を引き起こすことがあります。

市場セグメント分析

世界の甲状腺疾患治療市場は、疾患タイプ、薬剤クラス別、投与経路、流通チャネル、地域に基づいてセグメント化されます。

薬剤クラス別の甲状腺ホルモンは、甲状腺疾患治療市場シェアの約40.1％を占める

薬剤クラス別の甲状腺ホルモンの市場シェアは約40.1％です。甲状腺ホルモンは、甲状腺疾患、特に甲状腺機能低下症の治療に極めて重要です。レボチロキシンのようなホルモン補充療法は、甲状腺ホルモンの正常レベルを回復させ、代謝とエネルギーレベルを調整するために使用されます。

甲状腺機能低下症の有病率の増加と診断技術の向上が、これらの治療法の需要を押し上げています。甲状腺ホルモンレベルは、甲状腺機能亢進症、結節、甲状腺がんの治療を受けている患者においてモニターされ、管理されています。生涯治療としての甲状腺ホルモン補充への依存は、市場成長に大きく寄与しています。

例えば、2023年12月、FDAは甲状腺機能低下症の治療を目的とした経口溶液であるレボチロキシンナトリウム（Tirosint-SOL、IBSA）のラベルに2つの変更を承認しました。最初の変更点は、レボチロキシンナトリウムとプロトンポンプ阻害薬（PPI）療法の併用です。2つ目の変更点は、レボチロキシンナトリウムの投与タイミングです。

地域別の市場分析

北米は予測期間を通じて市場シェア全体の約38.4%を占めると推定される

北米は、有病率の増加、ヘルスケア施設の改善、一般市民の認知度、治療オプション、政府と製薬会社のプロモーション戦略などにより、予測期間を通じて市場全体の約38.4%を占めると推定されます。

例えば、2024年7月、米国食品医薬品局（FDA）は、RETと呼ばれる遺伝子に特定の変化を有する2歳以上の進行性または転移性甲状腺がんの成人および小児患者の治療薬として、標的治療薬セルペルカチニブ（レテブモ）を全面的に承認しました。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 甲状腺疾患の有病率の上昇
    • 研究開発の増加
  • 抑制要因
    • 薬剤に伴う合併症
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 特許分析
• PESTLE分析
• SWOT分析
• DMIオピニオン

第6章 疾患タイプ別

• 甲状腺機能低下症
• 甲状腺機能亢進症
• その他

第7章 薬剤クラス別

• チオ尿素誘導体
• プロピルチオウラシル
• 甲状腺ホルモン
• 電解質
• 副腎皮質ステロイド
• 三環系抗うつ薬
• 抗てんかん薬

第8章 投与経路別

• 経口
• 非経口
• その他

第9章 流通チャネル別

• 院内薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• GlaxoSmithKline PLC
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Abbvie Inc
• Amgen Inc
• Novartis AG
• Mylan NV
• Merck KGaA
• Pfizer Inc
• Takeda Pharmaceutical Company Limited
• Elexis Inc
• IBSA Pharma（IBSA Group）

第13章 付録

Report Overview

Global Thyroid Gland Disorders Therapeutics Market reached US$ 2.7 billion in 2023 and is expected to reach US$ 4.3 billion by 2031, growing at a CAGR of 6.3% during the forecast period 2024-2031

Thyroid gland disorders therapeutics involve medical interventions to treat abnormalities in thyroid function, such as hypothyroidism, hyperthyroidism, thyroid nodules, and thyroid cancer. Treatments include hormone replacement therapy, antithyroid medications, radioactive iodine, and surgical options. Advancements in molecular and targeted therapies improve treatment precision, providing more tailored solutions for patients. These treatments address metabolic imbalances caused by disrupted thyroid hormone production.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of thyroid disorders

The global thyroid gland disorders therapeutics market is experiencing growth due to the increasing prevalence of thyroid disorders like hypothyroidism, hyperthyroidism, thyroid nodules, and thyroid cancer. Factors like aging populations, genetic predispositions, and autoimmune diseases like Hashimoto's thyroiditis and Graves' disease are contributing to this increase.

For instance, according to America Thyroid Association, over 12 percent of the U.S. population will develop a thyroid condition, with 20 Billion Americans having some form of thyroid disease. Up to 60% of those with thyroid disease are unaware of their condition. Women are five to eight times more likely than men to have thyroid problems. One woman in eight will develop a thyroid disorder.

Most thyroid cancers respond to treatment, but a small percentage can be aggressive. Undiagnosed thyroid disease can lead to serious conditions like cardiovascular diseases, osteoporosis, and infertility. Pregnant women with undiagnosed or inadequately treated hypothyroidism have an increased risk of miscarriage and preterm delivery.

Complications associated with the drugs

Thyroid gland disorders can result in various side effects, depending on the treatment. Hormone replacement therapy, used in hypothyroidism, can cause weight gain, hair loss, heart palpitations, anxiety, and insomnia. Antithyroid medications, like methimazole and propylthiouracil, can cause liver toxicity, skin rashes, joint pain, and reduced white blood cell counts, increasing the risk of infections. Radioactive iodine therapy can lead to long-term hypothyroidism, requiring lifelong hormone replacement, and may cause dry mouth, salivary gland inflammation, or taste changes.

Market Segment Analysis

The global thyroid gland disorders therapeutics market is segmented based on disease type, drug class, route of administration, distribution channel, and region.

The thyroid hormones from the drug class segment accounted for approximately 40.1% of the thyroid gland disorders therapeutics market share

The thyroid hormones from the drug class segment accounted for approximately 40.1%. Thyroid hormones are crucial in treating thyroid disorders, especially hypothyroidism. Hormone replacement therapies like levothyroxine are used to restore normal levels of thyroid hormones, regulating metabolism and energy levels.

The increasing prevalence of hypothyroidism and improved diagnostic techniques have driven demand for these therapies. Thyroid hormone levels are monitored and managed in patients undergoing treatments for hyperthyroidism, nodules, and thyroid cancer. The reliance on thyroid hormone replacement as a lifelong treatment contributes significantly to market growth.

For instance, in December 2023, the FDA approved 2 changes to the label of levothyroxine sodium (Tirosint-SOL, IBSA), an oral solution that is aimed to treat hypothyroidism. The first change included the use of levothyroxine sodium combined with proton pump inhibitor (PPI) therapy. The second change included timing to administer levothyroxine sodium.

Market Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to increased prevalence, improved healthcare facilities, public awareness, and treatment options, as well as promotional strategies between governments and pharmaceutical companies.

For instance, in July 2024, the US Food and Drug Administration (FDA) granted full approval to the targeted therapy selpercatinib (Retevmo) for treating adult and pediatric patients 2 years and older with advanced or metastatic thyroid cancers that have certain changes in a gene called RET.

Market Segmentation

By Disease Type

Hypothyroidism

Hyperthyroidism

Others

By Drug Class

Thiourea derivatives

Propylthiouracil

Methimazole

Beta-adrenergic blocking agents

Propranolol

Others

Thyroid Hormones

Levothyroxine

Liothyronine

Others

Electrolytes

Potassium chloride

Others

Corticosteroids

Prednisone

Others

Tricyclic antidepressants

Amitriptyline

Others

Antiepileptic agents

Gabapentin

Others

By Route of Administration

Oral

Parenteral

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include GlaxoSmithKline PLC, Abbvie Inc,Amgen Inc, Novartis AG, Mylan NV, Merck KGaA, Pfizer Inc, Takeda Pharmaceutical Company Limited, Elexis Inc, IBSA Pharma (IBSA Group) among others.

Key Developments

In May 2023, Merck KGaA collaborated with the Executive Board of the Indonesian Medical Association and the Central Board of the Indonesian Thyroid Association to improve screening and diagnosis of thyroid disorders in Indonesia.

In December 2023, Aspen Pharmacare Holdings Limited made an agreement with Sandoz AG to acquire its Chinese business, helping to expand its presence in China by establishing a portfolio for future growth in the region.

Why Purchase the Report?

To visualize the global thyroid gland disorders therapeutics market segmentation based on disease type, drug class, route of administration, distribution channel, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the thyroid gland disorders therapeutics market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global thyroid gland disorders therapeutics market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Disease Type
• 3.2. Snippet by Drug Class
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in the prevalence of thyroid disorders
    • 4.1.1.2. Rise in the research and development
  • 4.1.2. Restraints
    • 4.1.2.1. Complications associated with the drugs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Patent Analysis
• 5.6. PESTLE Analysis
• 5.7. SWOT Analysis
• 5.8. DMI Opinion

6. By Disease Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 6.1.2. Market Attractiveness Index, By Disease Type
• 6.2. Hypothyroidism*
  • 6.2.1. Introduction
• 6.3. Hyperthyroidism
• 6.4. Others

7. By Drug Class

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
• 7.2. Market Attractiveness Index, By Drug Class
• 7.3. Thiourea derivatives*
  • 7.3.1. Introduction
  • 7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.4. Propylthiouracil
• 7.5. Thyroid Hormones
• 7.6. Electrolytes
• 7.7. Corticosteroids
• 7.8. Tricyclic antidepressants
• 7.9. Antiepileptic agents

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Parenteral
• 8.4. Others

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. UK
    • 10.3.7.3. France
    • 10.3.7.4. Italy
    • 10.3.7.5. Spain
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. GlaxoSmithKline PLC *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Abbvie Inc
• 12.3. Amgen Inc
• 12.4. Novartis AG
• 12.5. Mylan NV
• 12.6. Merck KGaA
• 12.7. Pfizer Inc
• 12.8. Takeda Pharmaceutical Company Limited
• 12.9. Elexis Inc
• 12.10. IBSA Pharma (IBSA Group) (*LIST NOT EXHAUSTIVE)

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us